Regenxbio stock maintains Outperform rating at Raymond James on MPS II data

Regenxbio (RGNX) received reaffirmed analyst confidence, with Raymond James reiterating an Outperform rating and $29 price target, following positive one-year data for its RGX-121 gene therapy for Hunter syndrome, which demonstrated significant biomarker reduction and neurodevelopmental benefits. However, the FDA extended the RGX-121 PDUFA date to February 2026, requesting additional data, amid broader regulatory uncertainty for gene therapies. Despite this delay and a recent price target reduction by RBC Capital, RGNX continues to advance its pipeline, notably with a Duchenne muscular dystrophy treatment expecting a Biologics License Application in mid-2026.

Analysis

Regenxbio (RGNX) presents a mixed but compelling profile, characterized by strong clinical data juxtaposed with significant regulatory delays. The company's RGX-121 gene therapy for Hunter syndrome demonstrated an 82% median reduction in a key cerebrospinal fluid biomarker and positive neurodevelopmental outcomes (BSID-III) at the one-year mark, prompting Raymond James to reiterate its Outperform rating and $29.00 price target. The firm views this data as a clear indicator of central nervous system benefit beyond existing therapies. However, this clinical promise is tempered by the U.S. FDA's decision to extend the PDUFA review timeline to February 8, 2026, introducing substantial uncertainty and pushing out a key catalyst. This delay is reflected in RBC Capital's decision to lower its price target to $17.00, despite maintaining an Outperform rating. While the stock has surged over 50% in the last six months and is noted as potentially undervalued, the extended regulatory pathway for RGX-121 and a future Biologics License Application for its Duchenne treatment not expected until mid-2026, suggest a long-term investment horizon with considerable event-driven volatility.

Key Decisions for Investors

• Investors with a long-term horizon and high risk tolerance could consider the strong clinical data for RGX-121 as a fundamental positive, potentially viewing any weakness from the PDUFA delay as a long-term entry point.
• Traders and risk-averse investors should recognize that the PDUFA extension to February 2026 creates a significant timeline risk, likely capping near-term upside and introducing a long period of uncertainty until the next major catalyst.
• It is critical to monitor for any further guidance from the FDA on gene therapies, interim data from the RGX-121 pivotal trial, and progress updates on the Duchenne muscular dystrophy program, which now carries more weight for mid-term valuation.